Retrospective Review of Esophageal Cancer at MSKCC
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.
Eligibility criteria
Qualifiers
Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
Pathologic staged T3 tumors (pT3)
Disqualifiers
Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
Patients undergoing salvage esophagectomy
Evidence of distant metastatic disease
Trial design
Treatments tested in this trial
- Esophagectomy
Treatment groups
4,000 Participants
are divided into 3 treatment groupsLocations
1Memorial Sloan Kettering Cancer Center (All Protocol Activities)10065, New YorkNew York, United States
Sponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Source ClinicalTrials.gov